Company intelligence / Profile preview
Verge Genomics
South San Francisco, California, United Statesvergegenomics.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
Verge Genomics has advanced its lead candidate VRG50635, a PIKfyve inhibitor for ALS treatment, into clinical trials. The company has demonstrated the ability to identify novel targets and develop them into clinical candidates using its AI platform.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Eli Lilly ($706 million partnership)Alexion/AstraZeneca Rare DiseaseFerrer
Beyond the preview
Go deeper on Verge Genomics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verge Genomics.